had a decrease in his monoclonal protein >50 % that did not persist. PK properties were similar to prior publications, and immunohistochemical staining for cyclin D1 and phospho-retinoblastoma did not predict response. Conclusions Flavopiridol as a single agent given by bolus and then infusion caused significant diarrhea, cytopenias, and transaminase elevation but only achieved marginal responses in relapsed myeloma (ClinicalTrials.gov identifier NCT00112723).
survival [16] , primarily due to bortezomib, a proteasome inhibitor, and immune modulators (IMiDs) thalidomide and lenalidomide [30] that lead to interferon regulatory factor-4 inhibition [17] and caspase-mediated apoptosis. The vast majority of myeloma patients will still die of progressive disease, leading to a search for novel agents.
Cyclin-dependent kinase (CDK) inhibition is an attractive target as MM cells are dependent on cell cycle dysregulation to overcome c-Myc-induced apoptosis [25, 27] . Cell cycling is regulated in part by CDK complexes, and therapeutic intervention to prevent their binding to cyclins is of interest in myeloma as most myeloma cells have high levels of cyclin D1, D2, and/or D3 [1] that phosphorylate retinoblastoma (RB), moving cell cycle progression forward. In vitro studies have shown marked decrease in myeloid cell leukemia-1 (MCL-1) and phospho-RNA polymerase II after sustained exposure to flavopiridol in U266 [9] , 8226 [24] , and OPM-2 [12] cell lines, but this could be overcome by overexpression of BCL-XL and BCL-2 and a resistance mechanism was suggested by late MCL-1 overexpression.
Flavopiridol targets the CDK 9/cyclin T complex (preventing activation of RNA polymerase II) [4, 8] , downregulates MCL-1 [12] , induces mitochondrial permeability changes [15] , and interrupts NF-κB pathway by inhibiting IκK [28] . It is highly protein bound when in human serum, requiring a 30-min intravenous bolus followed by 4-h intravenous infusion-with this hybrid infusional schedule, significant responses have been observed in patients with refractory chronic lymphocytic leukemia [3] .
Previous trials using dosing based on in vitro cytotoxicity were ineffective in patients with treated MM [9] thought to be from inadequate area under the concentration (AUC) levels reached. We designed a phase I dose escalation study to establish the maximum tolerated dose (MTD) and describe toxicities associated with a single agent flavopiridol in patients with relapsed myeloma.
Methods

Clinical trial
This study was approved by the Ohio State University Cancer Institutional Review Board, and informed consent was obtained from all enrolled patients. Adult patients were required to have symptomatic myeloma using criteria from the International Myeloma Working Group [10] and be seen as outpatients in the myeloma clinic at The Ohio State University Arthur G. James Hospital and Solove Research Institute. This trial was registered on clinicaltrials.gov as NCT00112723.
Patients with a diagnosis of relapsed myeloma after at least two prior treatments with no limit on prior therapies were included. Adequate organ function was required with creatinine ≤1.5 mg/dL and total bilirubin less than or equal to twice the institutional upper limit of normal. Adequate hematologic parameters were also required with a hemoglobin ≥9 g/dL, absolute neutrophil counter ≥1,500/μL, and platelets ≥50,000/μL; however, lower platelet values were allowed if attributable to the patient's underlying myeloma on screening bone marrow biopsy. Flavopiridol was administered weekly via central venous catheter as a 30-min intravenous bolus followed by a 4-h continuous intravenous infusion (CIV) for 4 weeks in a 6-week cycle.
Responses were recorded based on International Myeloma Working Group Criteria [11] .
Toxicity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0, until July 31, 2010, and version 4.0 beginning August 1, 2010. Dose-limiting toxicity (DLT) was defined as (1) any grade 3-4 non-hematologic toxicity (except leukopenia or neutropenia) that does not resolve or decrease to grade 1-2 within 2 weeks, or (2) any grade 4 hematologic toxicity that causes more than a 1-week delay in administration of therapy. Granulocyte colony-stimulating factor (G-CSF) was used at the discretion of the treating investigator. The MTD was defined as the dose level beneath the dose at which two or more of six patients experienced DLT.
Pharmacokinetic (PK) analysis
Plasma samples were obtained on days 1 and 22 of the first cycle. Sodium heparinized blood was obtained at the following time points: prior to dosing (t = 0), at 0.5, 1, 3, 4.5, 6, 8, and 24 h after the initiation of infusion on days 1 and 22. Blood samples were centrifuged, and plasma was stored at −70 °C until analysis. Flavopiridol quantification in plasma samples was achieved using a validated liquid chromatography-tandem mass spectrometry assay as previously described [22] . Plasma flavopiridol concentrationtime data were analyzed using standard non-compartmental methods in WinNonlin Professional v 5.2.1 (Pharsight, Mountain View, CA).
Immunohistochemical analysis
We hypothesized that cyclin D1 overexpression would sensitize myeloma cells to flavopiridol [7] . Immunohistochemical (IHC) staining for cyclin D1 (BCL-1) (Neomarkers) and retinoblastoma (RB-358, Leica), and phospho-RB (pRB, Leica) was performed on the 4-μm sections of formalin-fixed, paraffin-embedded (FFPE) bone marrow biopsy or clot sections. Briefly, sections were placed in a 60 °C oven for 1 h, cooled, and deparaffinized and rehydrated through xylenes and graded ethanol solutions to water. All slides were quenched for 5 min in 3 % hydrogen peroxide (v/v) for endogenous peroxidase. Antigen retrieval was performed by a heat method in which the specimens were placed in a citric acid solution (pH 6.1) for 25 min at 94 °C and cooled for 15 min. Slides were then placed on an autostainer (Dako Immunostaining) for immunohistochemistry. The antibodies for cyclin D1, RB, and pRB were used at a dilution of 1:100, 1:50, and 1:100, respectively, and incubated for 30 min at room temperature. The Envision Plus horseradish peroxidase (HRP) with 3,3′-diaminobenzidine (DAB) chromogen (Dako) was used to produce a brown precipitate. Slides were then counterstained in Richard Allen hematoxylin. A scoring system was developed from a single observer (author WZ) based on intensity for the majority of the stained plasma cells with 0-1 as negative, 2 as moderate, and 3 as strong.
Statistical analysis
This protocol is a standard 3 × 3 phase I dose escalation study of a single agent flavopiridol to determine the maximum tolerable dose of the agent to be used in a phase II evaluation of response. Separate, parallel phase I studies were conducted in each of six disease groups (indolent B cell NHL, mantle cell lymphoma, intermediate-grade B cell NHL, T/NK cell NHL, Hodgkin's lymphoma, and MM) in order to determine disease-specific DLT, MTD, and recommended phase II doses.
Spearman correlation analysis (two-tailed p values) was performed between clinical response and IHC staining results for BCL-1, RB, and pRB using Prism v 5.0F (GraphPad Software, San Diego, CA).
Statistical analyses for pharmacokinetic (PK) parameters were performed on all enrolled patients with evaluable PK data (n = 15); PK profiles that yielded ≥30 % estimated area under the concentration versus time curve from zero to infinity (AUC (0-∞) ) extrapolation were omitted from final analyses. Paired t tests were used to evaluate differences in AUC (0-∞) and C max between days 1 and 22 of cycle 1. The associations between PK parameter estimates and dose level were tested using one-way analysis of variance (ANOVA) and two-sample t tests or nonparametric tests when appropriate. Data are described with means ± SD and/or medians with ranges. These data were analyzed using SigmaPlot v11 (Systat Software Inc.).
Results
Patients
Fifteen patients (age 49-81 years) with relapsed myeloma were treated. The median number of prior therapies was 7 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . At the time of study entry, ten patients displayed 
Response
Immunoglobulins, free light chains, and 24-h urine samples were obtained using screening, and then the appropriate myeloma proteins were obtained on the first day of each subsequent cycle to follow response. There were no confirmed partial responses although one patient had a decrease in his monoclonal protein >50 %, which was not quite maintained with the second cycle and hence qualifies as a confirmed MR. Overall, there was one minor response, one patient with stable disease for three cycles, and the remainder suffered either progressive disease after the first cycle (4 patients) or did not continue on study treatment (9 patients).
The one patient with a minor response had an IgA myeloma with a t (4;14) , deletion chromosome 13, and tetraploid cytogenetics by FISH that had been treated with vincristine, doxorubicin, and high-dose dexamethasone (VAD) with progression, complete response with salvage bortezomib and dexamethasone, and then an autologous transplant from which he remained in a remission off maintenance therapy for three years until relapse then treatment on this clinical protocol (Table 1 ).
Toxicities
Grade 3/4 toxicities were significant (Table 2) . Cytopenias were considerable with grade 4 neutropenia (11 patients), grade 4 anemia (7 patients), and grade 4 thrombocytopenia (3 patients). Elevated transaminases (grade 4 in 3 patients, grade 3 in 4 patients, and grade 2 in 3 patients) were frequent but were asymptomatic and resolved in the periods between flavopiridol exposure. Diarrhea (grade 3 in 6 patients and grade 2 in 5 patients) was common but did not lead to hospitalization. There were two patients with neutropenic pneumonia and one patient with neutropenic fever.
There were eight serious adverse events related primarily to pancytopenia with or without infection, asymptomatic elevated transaminases, or progressive myeloma. Patient E (30/50) became febrile with grade 3 neutropenia after her initial infusion for which 20 mg intravenous dexamethasone was added to subsequent treatments. However, on day 20 of cycle 1, she became septic due to citrobacter bacteremia. Patient B (30/50) became infected day 2 of cycle 1 with pseudomonas bacteremia, and patient P (50/50) became pancytopenic and septic during cycle 1. Patients K (50/50) and J (30/50) both developed asymptomatic grade 4 elevated transaminases. On day 1 of cycle 2, patient C (30/50) developed mental status changes from hypercalcemia attributed to progressive disease. Patient G (30/50) developed grade 4 neutropenia and thrombocytopenia with cycle 1 and suffered a pathologic fracture just prior to treatment on day 1 of cycle 2 consistent with progressive disease. After progressing on therapy and receiving infusional dexamethasone-cyclophosphamide-etoposide-platinum (DCEP), patient R (50/50) became septic with grade 4 neutropenia and died within 30 days of his last dose of flavopiridol (Fig. 1 ).
Immunohistochemistry
Pretreatment biopsy or aspirate samples were stained for BCL-1 (cyclin D1, CCND1), RB, and pRB (Table 3) . A single reviewer scored the intensity of staining in plasma cells. RB staining was seen in all but one specimen. The intensity of BCL-1 and RB staining could not be statistically associated with response (p = 0.84 and p = 0.12, respectively), but intense staining was seen in two of the patients with stable disease. The staining intensity of pRB showed no correlation with response to flavopiridol (p = 0.88).
Pharmacokinetics
Plasma samples from 15 patients (a total of 24 concentration-time profiles with 187 plasma concentration observations) were available for analysis. Three PK profiles for three patients were omitted due to ≥30 % AUC (0-∞) extrapolation, resulting in 14 plasma flavopiridol concentration-time profiles on day 1 and seven profiles on day 22 (Fig. 2) . Data points for determining the terminal elimination phase (λz) were selected automatically in WinNonlin, and resulting λz ranges were determined to be adequate by manual review. Three dose levels, ranging from total dose (bolus + maintenance) of 60-100 mg/m 2 , were administered in this study. Among those with PK data on both days 1 and 22 (n = 6), the mean differences in AUC (0-∞) and C max for day 22 versus day 1 were not significant (p = 0.53 and p = 0.57, respectively), where the average difference in AUC (0-∞) was 1.00 h μM (95 % CI −2.78 to 4.78 h μM) and the average difference in C max was 0.153 μM (95 % CI −0.50 to 0.80 μM). There was no statistically significant difference between the apparent volume of distribution based on terminal phase (Vz), total body clearance (CL), and terminal phase elimination half-life (T 1/2 ) for the 2 dosing days in these same individuals. PK parameter data from days 1 and 22 of cycle 1 combined are summarized in Table 4 . When the PK parameter estimates for day 1 cycle 1 were compared between the three dose levels, a significantly higher mean AUC (0-∞) was observed for dose level 3 compared to dose level 2 (p < 0.05; Fig. 3a) . The mean AUC (0-∞) for dose level 2 was unexpectedly lower than that of dose level 1, likely because there were only three concentration profiles available for evaluation for this dose level. The mean AUC (0-∞) for dose level 3 was higher when compared to dose level 1, but not statistically significant. The differences in mean C max of all dose levels were insignificant (Fig. 3b) . The mean T max was longer in the 30/50 and 50/50 mg/m 2 dose level groups Immunohistochemistry on paraffin-embedded bone marrow core tissue was performed for BCL-1, retinoblastoma (RB), and phospho-RB (pRB), and patient IDs were sorted from best response to worst response when possible. A score was assigned which represents the intensity for the majority of stained plasma cells. 0-1+ will be considered as negative, 2+ as moderate, and 3+ as strong. The majority of the pRB stains are in agreement with RB, but patients G and M were not. Patients I, L, and P had inadequate plasma cells for staining and are not listed. Best response per IMWG was listed whenever possible ID Best response BCL-1 RB pRB
compared to 30/30 mg/m 2 (1.18 ± 1.22, 1.40 ± 1.67 h, and 0.52 ± 0.03, respectively). However, it should be noted that there was one outlier in the 30/50 mg/m 2 dose level group (3.0 h) and two outliers (4.6 and 4.5 h) in the latter group. The medians T max were comparable among the three dose levels.
There were also no large differences in Vz and T 1/2 of flavopiridol among the three dose levels. The clearance parameters estimated here, except for the 30/50 mg/ m 2 dose level, were very comparable to the previously published data [2] . Based on a two-compartment population PK model with first-order elimination, we previously reported flavopiridol clearance of 31.4 ± 5.4 L/hr [21] . In this study, the mean CL for the 30/30 and 50/50 mg/ m 2 dose levels were 39.97 ± 20.87 and 38.56 ± 14.26 L/ hr, respectively. The CL estimated from the 30/50 mg/m 2 group was significantly higher than the other two groups (p < 0.005). This is consistent with the lower mean AUC estimated as presented above, and this unexpected result should be interpreted cautiously and may be attributed to the small sample size. Overall, PKs appear comparable to that reported for flavopiridol in other hematologic malignancies [2, 3, 21] .
Discussion
In this phase I trial of flavopiridol in relapsed MM, we determined the MTD at 50 mg/m 2 30-min bolus followed by 50 mg/m 2 4-h CIV. With only one documented marginal response, we did not feel that there was adequate singleagent activity to continue into the phase II portion of the trial.
CDK inhibition is a tempting therapeutic target because increased expression of at least one of the three CCND genes is a near-universal event in plasma cell dyscrasias [1] ; CCND1 is expressed in hyperdiploid myeloma, while CCND2 is expressed by most of the remaining tumors. D-type cyclins are critical regulators of the cell cycle that act in a complex with CDKs −4 or −6 to promote the phosphorylation of the RB protein to initiate cellular transition from G 1 to S phase [5, 6, 19, 26] . Focal amplification of cyclin D1 may be required for CDK inhibitors to keep p21 CIP1 level low and inactivate NF-κB [15] , while RB1 mutations or deletions may lead to resistance to flavopiridol as with other CDK inhibitors, or perhaps resistance could be mediated by autophagy as it is in CLL [18] . Notably in our trial, IHC staining for BCL-1 and pRB was unable to demonstrate a correlation between the staining and response-this staining was exploratory as a phosphorylated antibody in bone marrow samples has not been validated and IHC analysis is semiquantitative at best. In a phase Ib study of flavopiridol in combination with bortezomib [13] , responses were seen in bortezomib-naïve myeloma patients, confirming the molecular studies [20] demonstrating that resistance to bortezomib and CDK inhibitors overlaps.
Flavopiridol led to considerable adverse events in this patient population, and responses were generally shortlived. It is possible that the higher doses used in this patient population in the final cohort represent responses that we would see more commonly at even higher doses, but unfortunately off-target effects of neutropenia and diarrhea would prevent further dose escalation. Flavopiridol is no longer being pursued in lymphoproliferative diseases, but ongoing trials are accruing in combination in myeloid neoplasms in combination with standard cytotoxic agents. Preclinical evaluation of the CDK inhibitor AT7519 has demonstrated the importance of glycogen synthase kinase-3β for apoptosis [23] , but this testing has not been performed with most other CDK inhibitors including flavopiridol. The precise anti-neoplastic mechanism of action of CDK inhibitors in myeloma remains controversial.
In summary, this phase I trial established the MTD of a single agent flavopiridol MTD to be 50 mg/m 2 30-min bolus followed by 50 mg/m 2 4-h CIV. The clinical evaluation of CDK inhibitors in MM has been hampered by tight therapeutic indices [3, 29] and lack of efficacy in early phase studies. Novel agents with broader CDK inhibition [20, 23] and wider therapeutic indices relative to flavopiridol are needed with compounds such as SCH-72765 and TG-02 in phase 3 and 1 clinical trials, targeted toward patients most likely to respond with p16 or p18 deletions.
